1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Arlington VA: 2013. American Psychiatric Publishing.
2. Hartlage S, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69: 300–5. DOI: 10.1001/archgenpsychiatry.2011.1368
3. Вольфф М. Гинекологическая эндокринология и репродуктивная медицина. Пер. с нем. под общ. ред. Е.Н.Андреевой. М.: МЕДпресс-информ, 2017.
[Vol'ff M. Ginekologicheskaia endokrinologiia i reproduktivnaia meditsina. Per. s nem. pod obshch. red. E.N.Andreevoi. Moscow: MEDpress-inform, 2017 (in Russian).]
4. Appleton SM. Premenstrual Syndrome: Evidence-based Evaluation and Treatment. Clin Obstet Gynecol 2018; 61 (1): 52–61. DOI: 10.1097/GRF.0000000000000339
5. Heinemann LA, Mihn TD, Heinemann K et al. Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women Int 2012; 33: 109–24. DOI: 10.1080/07399332.2011.610530
6. Chocano-Bedoya PO, Manson JE, Hankinson SE et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr 2011; 93 (5): 1080–6. DOI: 10.3945/ajcn.110.009530
7. Hashemi S, Ramezani Tehrani F, Mohammadi N et al. Comparison of Metabolic and Hormonal Profiles of Women With and Without Premenstrual Syndrome: A Community Based Cross-Sectional Study. Int J Endocrinol Metab 2016; 14: e28422. DOI: 10.5812/ijem.28422
8. Bertone-Johnson E, Hankinson S, Willett W et al. Adiposity and the development of premenstrual syndrome. J Womens Health (Larchmt) 2010; 19: 1955–62. DOI: 10.1089/jwh.2010.2128
9. Perkonigg A, Yonkers K, Pfister H et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65: 1314–22.
10. Graze K, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81: 201–5.
11. Kendler K, Silberg J, Neale M et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992; 22: 85–100.
12. Schmidt P, Martinez P, Nieman L et al. Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. Am J Psychiatry 2017: appiajp201716101113. DOI: 10.1176/appi.ajp.2017.16101113
13. Bixo M, Ekberg K, Poromaa IS et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology 2017; 80: 46–55. DOI: 10.1016/j.psyneuen.2017.02.031
14. Gracia C, Freeman E, Sammel M et al. Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol 2009; 29: 403–5. DOI: 10.1097/JCP.0b013e3181ad8825
15. Eriksson E. SSRIs probably counteract premenstrual syndrome by inhibiting the serotonin transporter. J Psychopharmacol 2014; 28: 173–4. DOI: 10.1177/0269881113512910
16. Hiroi R, Mcdevitt R, Neumaier JF. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 2006; 60: 288–95.
17. Bertone-Johnson ER, Whitcomb BW, Rich-Edwards JW et al. Premenstrual Syndrome and Subsequent Risk of Hypertension in a Prospective Study. Am J Epidemiol 2015; 182 (12): 1000–9. DOI: 10.1093/aje/kwv159
18. Bertone-Johnson ER, Houghton SC, Whitcomb BW et al. Association of Premenstrual Syndrome with Blood Pressure in Young Adult Women.
J Womens Health (Larchmt) 2016; 25 (11): 1122–8.
19. Liu R, Mi B, Zhao Y et al. Effect of B Vitamins from Diet on Hypertension. Arch Med Res 2017; 48 (2): 187–94. DOI: 10.1016/j.arcmed.2017.03.011
20. Bender A, Hagan KE, Kingston N. The association of folate and depression: A meta-analysis. J Psychiatr Res 2017; 95: 9–18. DOI: 10.1016/j.jpsychires.2017.07.019
21. Briguglio M, Dell'Osso B, Panzica G et al. Dietary Neurotransmitters: A Narrative Review on Current Knowledge. Nutrients 2018; 10 (5). pii: E591. DOI: 10.3390/nu10050591
22. Isgin-Atici K, Buyuktuncer Z, Akgül S, Kanbur N. Adolescents with premenstrual syndrome: not only what you eat but also how you eat matters! J Pediatr Endocrinol Metab 2018; 31 (11): 1231–9. DOI: 10.1515/jpem-2018-0125
23. Farasati N, Siassi F, Koohdani F et al. Western dietary pattern is related to premenstrual syndrome: a case-control study. Br J Nutr 2015; 114: 2016–21. DOI: 10.1017/S0007114515003943
24. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41–9.
25. Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt) 2009; 18: 895–9. DOI: 10.1089/jwh.2008.1098
26. Green L, O' Brien P, Panay N, Craig M. Gynaecologists RCOOA. Management of premenstrual symptoms. Br J Obst Gynaecol 2016; 124: e73-e105.
27. Hunter M, Ussher J, Browne S et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193–9.
28. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: e407–e429.
29. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322: 134–7.
30. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment ofpremenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18: 191–5.
31. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013; 6: CD 001396. DOI: 10.1002/14651858. CD001396.pub3
32. Freeman EW, Rickels K, Yonkers KA et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98 (pt 1): 737–44.
33. Nevatte T, O’Brien PM, Backstrom T et al.; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013; 16: 279–91. DOI: 10.1007/s00737-013-0346-y
34. Hunter MS, Ussher JM, Browne SJ et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193–9.
35. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration.
Am J Obstet Gynecol 2003; 189: 1523–30.
36. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
37. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2: CD006586. DOI: 10.1002/14651858.CD006586.pub4
38. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol 2018; 218 (1): 68–74. DOI: 10.1016/j.ajog.2017.05.045
39. Giribela CR, Consolim-Colombo FM, Nisenbaum MG et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol 2015; 31 (11): 912–5. DOI: 10.3109/09513590.2015.1062860
40. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 2014; 89: 253–63. DOI: 10.1016/j.contraception.2014.01.023
41. Wang M, Hammarbäck S, Lindhe BA, Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74: 803–8.
42. Brown CS, Ling FW, Andersen RN et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779–86.
43. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19: 2152–5.

________________________________________________

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed). Arlington VA: 2013. American Psychiatric Publishing.
2. Hartlage S, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69: 300–5. DOI: 10.1001/archgenpsychiatry.2011.1368
3. Vol'ff M. Ginekologicheskaia endokrinologiia i reproduktivnaia meditsina. Per. s nem. pod obshch. red. E.N.Andreevoi. Moscow: MEDpress-inform, 2017 (in Russian).
4. Appleton SM. Premenstrual Syndrome: Evidence-based Evaluation and Treatment. Clin Obstet Gynecol 2018; 61 (1): 52–61. DOI: 10.1097/GRF.0000000000000339
5. Heinemann LA, Mihn TD, Heinemann K et al. Intercountry assessment of the impact of severe premenstrual disorders on work and daily activities. Health Care Women Int 2012; 33: 109–24. DOI: 10.1080/07399332.2011.610530
6. Chocano-Bedoya PO, Manson JE, Hankinson SE et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr 2011; 93 (5): 1080–6. DOI: 10.3945/ajcn.110.009530
7. Hashemi S, Ramezani Tehrani F, Mohammadi N et al. Comparison of Metabolic and Hormonal Profiles of Women With and Without Premenstrual Syndrome: A Community Based Cross-Sectional Study. Int J Endocrinol Metab 2016; 14: e28422. DOI: 10.5812/ijem.28422
8. Bertone-Johnson E, Hankinson S, Willett W et al. Adiposity and the development of premenstrual syndrome. J Womens Health (Larchmt) 2010; 19: 1955–62. DOI: 10.1089/jwh.2010.2128
9. Perkonigg A, Yonkers K, Pfister H et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65: 1314–22.
10. Graze K, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81: 201–5.
11. Kendler K, Silberg J, Neale M et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992; 22: 85–100.
12. Schmidt P, Martinez P, Nieman L et al. Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. Am J Psychiatry 2017: appiajp201716101113. DOI: 10.1176/appi.ajp.2017.16101113
13. Bixo M, Ekberg K, Poromaa IS et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology 2017; 80: 46–55. DOI: 10.1016/j.psyneuen.2017.02.031
14. Gracia C, Freeman E, Sammel M et al. Allopregnanolone levels before and after selective serotonin reuptake inhibitor treatment of premenstrual symptoms. J Clin Psychopharmacol 2009; 29: 403–5. DOI: 10.1097/JCP.0b013e3181ad8825
15. Eriksson E. SSRIs probably counteract premenstrual syndrome by inhibiting the serotonin transporter. J Psychopharmacol 2014; 28: 173–4. DOI: 10.1177/0269881113512910
16. Hiroi R, Mcdevitt R, Neumaier JF. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 2006; 60: 288–95.
17. Bertone-Johnson ER, Whitcomb BW, Rich-Edwards JW et al. Premenstrual Syndrome and Subsequent Risk of Hypertension in a Prospective Study. Am J Epidemiol 2015; 182 (12): 1000–9. DOI: 10.1093/aje/kwv159
18. Bertone-Johnson ER, Houghton SC, Whitcomb BW et al. Association of Premenstrual Syndrome with Blood Pressure in Young Adult Women.
J Womens Health (Larchmt) 2016; 25 (11): 1122–8.
19. Liu R, Mi B, Zhao Y et al. Effect of B Vitamins from Diet on Hypertension. Arch Med Res 2017; 48 (2): 187–94. DOI: 10.1016/j.arcmed.2017.03.011
20. Bender A, Hagan KE, Kingston N. The association of folate and depression: A meta-analysis. J Psychiatr Res 2017; 95: 9–18. DOI: 10.1016/j.jpsychires.2017.07.019
21. Briguglio M, Dell'Osso B, Panzica G et al. Dietary Neurotransmitters: A Narrative Review on Current Knowledge. Nutrients 2018; 10 (5). pii: E591. DOI: 10.3390/nu10050591
22. Isgin-Atici K, Buyuktuncer Z, Akgül S, Kanbur N. Adolescents with premenstrual syndrome: not only what you eat but also how you eat matters! J Pediatr Endocrinol Metab 2018; 31 (11): 1231–9. DOI: 10.1515/jpem-2018-0125
23. Farasati N, Siassi F, Koohdani F et al. Western dietary pattern is related to premenstrual syndrome: a case-control study. Br J Nutr 2015; 114: 2016–21. DOI: 10.1017/S0007114515003943
24. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41–9.
25. Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Womens Health (Larchmt) 2009; 18: 895–9. DOI: 10.1089/jwh.2008.1098
26. Green L, O' Brien P, Panay N, Craig M. Gynaecologists RCOOA. Management of premenstrual symptoms. Br J Obst Gynaecol 2016; 124: e73-e105.
27. Hunter M, Ussher J, Browne S et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193–9.
28. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16: e407–e429.
29. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322: 134–7.
30. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment ofpremenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18: 191–5.
31. Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2013; 6: CD 001396. DOI: 10.1002/14651858. CD001396.pub3
32. Freeman EW, Rickels K, Yonkers KA et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98 (pt 1): 737–44.
33. Nevatte T, O’Brien PM, Backstrom T et al.; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013; 16: 279–91. DOI: 10.1007/s00737-013-0346-y
34. Hunter MS, Ussher JM, Browne SJ et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002; 23: 193–9.
35. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration.
Am J Obstet Gynecol 2003; 189: 1523–30.
36. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
37. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2: CD006586. DOI: 10.1002/14651858.CD006586.pub4
38. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol 2018; 218 (1): 68–74. DOI: 10.1016/j.ajog.2017.05.045
39. Giribela CR, Consolim-Colombo FM, Nisenbaum MG et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol 2015; 31 (11): 912–5. DOI: 10.3109/09513590.2015.1062860
40. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 2014; 89: 253–63. DOI: 10.1016/j.contraception.2014.01.023
41. Wang M, Hammarbäck S, Lindhe BA, Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand 1995; 74: 803–8.
42. Brown CS, Ling FW, Andersen RN et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779–86.
43. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19: 2152–5.

Е.Н. Андреева1,2, Ю.С. Абсатарова*1

1. ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия;
2. ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*korsil2008@yandex.ru

________________________________________________

Elena N. Andreeva1,2, Yulia S. Absatarova*1

1. Endocrinology Research Centre, Moscow, Russia;
2. A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*korsil2008@yandex.ru